Structural Modification of the P2‘ Position of 2,7-Dialkyl-Substituted 5( S )-Amino-4( S )-hydroxy-8-phenyl-octanecarboxamides: The Discovery of Aliskiren, a Potent Nonpeptide Human Renin Inhibitor Active after Once Daily Dosing in Marmosets

Citations Over TimeTop 10% of 2007 papers

Abstract

Due to its function in the rate limiting initial step of the renin-angiotensin system, renin is a particularly promising target for drugs designed to control hypertension, a growing risk to health worldwide. Despite vast efforts over more than two decades, no orally efficacious renin inhibitor had reached the market. As a result of a structure-based topological design approach, we have identified a novel class of small-molecule inhibitors with good oral blood-pressure lowering effects in primates. Further lead optimization aimed for improvement of in vivo potency and duration of action, mainly by P2' modifications at the hydroxyethylene transition-state isostere. These efforts resulted in the discovery of aliskiren (46, CGP060536B, SPP100), a highly potent, selective inhibitor of renin, demonstrating excellent efficacy in sodium-depleted marmosets after oral administration, with sustained duration of action in reducing dose-dependently mean arterial blood pressure. Aliskiren has recently received regulatory approval by the U.S. Food and Drug Administration for the treatment of hypertension.

Related Papers

• → Structure-based design of aliskiren, a novel orally effective renin inhibitor(2003)502 cited
• → Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100)(2002)407 cited
• → Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro(2010)40 cited
• → An Improved and Economical Process for the Manufacture of the Key Intermediate of Aliskiren, a New Potent Renin Inhibitor(2013)11 cited
• → Protective effects of aliskiren, a direct renin inhibitor, in rats with acute pancreatitis(2014)1 cited